

## Our History and Our Promise

We are proud of our longstanding history of supporting over 240 product approvals. Since our founding in 1987 we have grown our scale and clinical development acumen to become the innovative, full-service CRO we are today. By aligning our operational excellence, deep therapeutic expertise, and appropriate technology, Synteract continues to be perfectly positioned to advance innovative therapies for patients who need them.

So, WHY SYNTERACT? The answer is because what we do is what we say. That is our promise. It is what our caring and highly skilled people have done, and will do every day. We are passionate about fulfilling this promise for our clients...because patients are waiting.

## Bringing Clinical Trials To Life"

Just as our clients do, all of us at Synteract dedicate ourselves to bringing a better future to patients. Improving the quality of human lives: it is why we are all in this industry.

We listen and collaborate with each of our clients to strategically adapt our services to support their specific needs. These include:

- Feasibility
- Project Management
- Clinical Operations
- Data Management
- Biostatistics
- Submission Dossier Prep

- Medical Affairs
- Regulatory Affairs
- Safety Services
- Functional Service Provision
- PKPD Simulation & Modeling

4,000+ CLINICAL TRIALS

750,000+ PATIENTS

62+ COUNTRIES



## Our Core Centers of Development

**Dermatology:** Our work is on novel and in-demand dermatology drug development across multiple indications. We have established strong relationships with clients and investigators.

**General Medicine:** We address the needs of customers who continue to seek our support in other therapeutic areas where we have built deep expertise, especially in Endocrine & Metabolic, Gastroenterology, Immunology & Inflammatory, Infectious Disease & Vaccines, and Women's Health.

**Oncology:** We have deep knowledge across numerous cancer types and hematological malignancies. We were one of the first CROs, 10+ years ago, to begin working on breakthrough immunotherapy trials.

**Neuroscience:** As neurology, pain and psychiatry studies become more complex, so does the burden of study participation on patients and their caregivers. Our goal is to make it as easy as possible to participate.

**Pediatrics:** We deliver a single source model for preclinical and clinical development, along with the specialized understanding it takes to conduct studies with children and their families.

**Rare/Orphan:** We specialize in studies for diseases that affect a small portion of the population, having conducted more than 195 trials in rare and/or orphan diseases, covering a wide range of therapeutic indications.



Synteract.com